Equillium announces positive topline data from phase 2 study of eq101 in alopecia areata

La jolla, calif.--(business wire)---- $eq--equillium inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from its phase 2, single dose, proof-of-concept (poc) study of eq101 in adult patients with moderate, severe or very-severe alopecia areata (aa), an autoimmune disease driven by an immune cell attack of the hair follicles th.
EQ Ratings Summary
EQ Quant Ranking